Genesystem Co., Ltd. (KOSDAQ:363250)

Market Cap	71.10B
Revenue (ttm)	1.21B
Net Income (ttm)	-8.92B
Shares Out	7.03M
EPS (ttm)	-1,302.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	70,538
Average Volume	39,847
Open	10,200
Previous Close	10,040
Day's Range	10,080 - 10,690
52-Week Range	5,800 - 12,800
Beta	0.60
RSI	45.23
Earnings Date	Jun 19, 2025

About Genesystem

Genesystem Co., Ltd., a biotech engineering company, specializes in molecular testing solutions to target on-site testing needs. The company offers PCR systems, multiplex biochips, and PCR reagents. It also provides human pathogen assays, including novel coronavirus (SARS-CoV-2) detection kits, SARS-CoV-2/Flu/RSV simultaneous detection kits, and mycobacterium tuberculosis detection kits; veterinary diagnostics; food safety assays comprising foodborne pathogen detection kits, HALAL food testing kits, and meat species identification kits; and nuc...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 363250

Financial Performance

In 2024, Genesystem's revenue was 1.21 billion, an increase of 34.64% compared to the previous year's 897.03 million. Losses were -8.92 billion, 12.6% more than in 2023.